… , will give BioMarin treatments for rare genetic diseases that generated … is caused by a genetic mutation that allows fatty … and organs, according the BioMarin. The second treatment … genetic condition that causes muscle weakness that worsens over time. BioMarin …

… and June next year. BioMarin expects Amicus’ medicines to … treat “Fabry disease,” a genetic, potentially life-threatening illness … is “fairly large” by BioMarin’s standards, and therefore … “overwhelmingly focused.” Given that BioMarin had become “one of …

… strengthens BioMarin's portfolio with Amicus' approved genetic … for Pompe disease, a genetic condition in which a … as focal segmental glomerulosclerosis. BioMarin intends to finance the … after the ‍transaction closes, ⁠BioMarin said. The deal is …

… maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN … a strong pipeline topped by BioMarin Pharmaceutical Inc. ‘s … position in the market. ​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) … root causes of rare genetic conditions. While we acknowledge …

… about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding … We’re driving initiatives like genetic reclassification, clinician education and patient … high free CNP exposures, human genetics, where natural CNP pathway …

… This decision is consistent with BioMarin’s portfolio strategy and … of research developing a genetic medicine for hemophilia A. … in peak sales, and BioMarin was similarly optimistic, estimating … therapy.  Last August, BioMarin pared down Roctavian spending …

… hemophilia A, a rare genetic disorder where the blood doesn … $26 million in 2024. BioMarin had initially projected Roctavian would … Elliott reached a deal with BioMarin to appoint three new independent … the company’s operations. BioMarin said it will now focus …

… 4998437 Conference ID: 4998437 About BioMarin BioMarin is a leading, global rare … development, BioMarin seeks to unleash the full potential of genetic science … the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, …

… and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement … achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively …

… -ever therapy for the rare, genetic disorder characterized by short stature … analogs,” Tsai said. Of course, BioMarin, currently the undisputed achondroplasia leader … instance, BioMarin has a late-stage program for hypochondroplasia, a genetic disorder …